Newer migraine drugs linked to higher miscarriage risk in early pregnancy
Representative image: Marncom / Pixabay
A JAMA Neurology study published October 12, 2026 links early-pregnancy use of anti-CGRP migraine antibodies to about 40% higher miscarriage risk.
What Happened
A study published online in the journal JAMA Neurology on October 12, 2026 has found that women who used a newer class of migraine-prevention drugs, known as anti-CGRP monoclonal antibodies, in early pregnancy had a higher risk of miscarriage than comparable women who did not. The researchers, led by a team including Flatman and Bérard, analysed 7,579 single-baby pregnancies among people who had migraine before pregnancy, using United States insurance claims data, and followed them up to 20 weeks of pregnancy. Reports on the study put the increase in risk at about 40 per cent, with an adjusted figure of about 42 per cent. An older migraine medicine, propranolol, was not linked to a higher risk.
Key Facts
- Published: JAMA Neurology, online, October 12, 2026.
- Data: 7,579 singleton pregnancies in people with migraine before pregnancy, from a US claims-based cohort, followed to 20 weeks.
- Finding: early-pregnancy exposure to anti-CGRP antibodies was linked to about 40% higher risk of miscarriage (reported adjusted figure about 42%).
- Comparison drug: propranolol, a long-used migraine preventive, showed no increased risk.
- Timing: coverage of an earlier presentation said the extra risk was concentrated between weeks 8 and 12.
- One summary of the findings estimated the baseline rate of clinically detected miscarriage at 6-8%, rising to about 8-11% with exposure.
- The study is observational: it shows a link, not proof that the drugs cause miscarriage.
Why It Matters
Migraine affects many women in the years when they may be planning a family, so the safety of migraine medicines in pregnancy is a practical question for a large number of patients. The anti-CGRP antibodies block a protein called calcitonin gene-related peptide, which is involved in migraine attacks, and are used to prevent frequent migraines. Until this study, the evidence on what they mean for early pregnancy came mainly from small case reports.
The findings matter because not every pregnancy is planned, and some women may still be using the medicine when they find out they are pregnant. The study's comparison with propranolol is also useful: it suggests that the higher risk is linked to the anti-CGRP drugs rather than to migraine itself, since women with migraine on propranolol did not show the same rise. For women who use these medicines, the practical message from the coverage is to discuss contraception and pregnancy plans with their doctor.
The evidence has limits. The study pooled several anti-CGRP antibodies together rather than reporting each drug separately. Insurance data can miss early miscarriages that never reach a doctor. And an earlier small case series published in 2024, covering six pregnancies with a review of the literature, did not find a clear increase in pregnancy problems. The authors and commentators have called for more research.
| Measure | Detail |
|---|---|
| Pregnancies studied | 7,579, all with migraine before pregnancy |
| Data source | US commercial insurance claims |
| Risk with anti-CGRP antibodies | About 40% higher (adjusted about 42%) |
| Risk with propranolol | No increase found |
| Published | October 12, 2026, JAMA Neurology |
Impact
Short-term: Neurologists and gynaecologists are likely to use the study in counselling women with migraine who are pregnant or planning to be. Women already on these medicines should not stop or change treatment on their own, but can raise the findings with their doctor.
Long-term: The study may prompt drug regulators and medical societies to review guidance on these medicines for women of reproductive age, and is likely to spur larger studies that look at each drug separately and at later pregnancy outcomes.
Who is affected: Women with migraine who are pregnant, planning a pregnancy or could become pregnant; their neurologists, gynaecologists and family doctors; and drug makers producing anti-CGRP medicines.
Key Takeaway
A large new study links anti-CGRP migraine drugs in early pregnancy to about 40 per cent higher miscarriage risk, so women of reproductive age using them should discuss pregnancy plans with their doctor.
Questions and Answers
Do newer migraine drugs increase the risk of miscarriage?
A JAMA Neurology study published on October 12, 2026 found that use of anti-CGRP monoclonal antibodies in early pregnancy was linked to about 40 per cent higher miscarriage risk. It is an observational study, so it shows an association, not proof of cause.
What are anti-CGRP migraine drugs?
They are antibody medicines that block calcitonin gene-related peptide, a protein involved in migraine attacks. They are used to prevent frequent migraines.
Should I stop my migraine medicine if I am pregnant?
Do not stop or change any medicine without medical advice. Speak to your doctor as soon as possible, who can weigh the risks of the drug against the risks of untreated migraine.
Was any migraine medicine found to be safer in the study?
Propranolol, an older drug used to prevent migraine, was not linked to a higher risk of miscarriage in the study.
Disclaimer: Prepared by the Peepals newsroom from publicly available sources with AI assistance. Information is accurate to the best of our knowledge at the time of publication and may change. Images may be representative. Not professional advice. Report an error via our contact page.
Sourced and fact-checked by the Peepals Global Editorial Team
44% of women feel more positive about life after menopause, survey finds
Radhika Ambani's hand-painted Kalamkari look puts craft at centre of Swadesh event
Reported, fact-checked and published by the Peepals Global Editorial Team.
